secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001558370-21-014000
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Q3 cash $101.9M; uproleselan Phase 3 enrollment nearing completion
--------------------------------------------------------------------------------

- Cash and cash equivalents $101.9M at Sept 30, 2021, down from $137.0M at Dec 31, 2020.
- R&D expenses increased to $13.3M from $10.7M YoY, driven by Phase 3 trial costs.
- Phase 3 trial of uproleselan in relapsed/refractory AML nearing enrollment completion; top line data after 2022.
- Data published in BLOOD showed 69% MRD negative rate in evaluable relapsed/refractory AML patients.
- New CEO Harout Semerjian appointed effective August 6, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837021014000/0001558370-21-014000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837021014000/glyc-20211102x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-014000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer